A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
暂无分享,去创建一个
Jia Liu | Ping Li | Xin Chen | D. Faustman | J. Oppenheim | De Yang | D. Tross | Fengyang Chen | Md Masud Alam | Mengmeng Jiang | Feng-Yang Chen
[1] G. Uzan,et al. TNFR2 Is a Crucial Hub Controlling Mesenchymal Stem Cell Biological and Functional Properties , 2020, Frontiers in Cell and Developmental Biology.
[2] B. Salomon,et al. The TNF/TNFR2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect , 2020, Cell Communication and Signaling.
[3] D. Faustman,et al. TNFR2 blockade alone or in combination with PD‐1 blockade shows therapeutic efficacy in murine cancer models , 2020, Journal of leukocyte biology.
[4] Zachary L. Skidmore,et al. Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade. , 2019, Blood.
[5] Fangxuan Li,et al. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis , 2019, Cancer medicine.
[6] M. Feldmann,et al. TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells , 2019, Proceedings of the National Academy of Sciences.
[7] S. Sakaguchi,et al. Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. , 2019, Immunity.
[8] J. Oppenheim,et al. HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways , 2018, Front. Immunol..
[9] M. Khodadoust,et al. Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome , 2018, Leukemia.
[10] D. Klatzmann,et al. Regulatory T cells in the treatment of disease , 2018, Nature Reviews Drug Discovery.
[11] Min Zhang,et al. The Significance of Tumor Necrosis Factor Receptor Type II in CD8+ Regulatory T Cells and CD8+ Effector T Cells , 2018, Front. Immunol..
[12] F. Pan,et al. The regulation of immune tolerance by FOXP3 , 2017, Nature Reviews Immunology.
[13] Xin Chen,et al. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors , 2017, Scientific Reports.
[14] R. Minter,et al. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy , 2016, Oncotarget.
[15] C. Le,et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. , 2016, Blood.
[16] A. Azmi,et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.
[17] Hong-Chiang Chang,et al. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA‐541→androgen receptor (AR)→MMP9 signaling , 2015, Molecular oncology.
[18] D. Männel,et al. Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity , 2014, Immunity, inflammation and disease.
[19] A. Wei,et al. Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients , 2013, Clinical Cancer Research.
[20] George Coukos,et al. T-regulatory cells: key players in tumor immune escape and angiogenesis. , 2012, Cancer research.
[21] M. Bustin,et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses , 2012, The Journal of experimental medicine.
[22] M. Gold,et al. TNFR1 delivers pro‐survival signals that are required for limiting TNFR2‐dependent activation‐induced cell death (AICD) in CD8+ T cells , 2011, European journal of immunology.
[23] A. Herbelin,et al. The TLR7 Agonist R848 Alleviates Allergic Inflammation by Targeting Invariant NKT Cells To Produce IFN-γ , 2011, The Journal of Immunology.
[24] Xin Chen,et al. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. , 2010, Current directions in autoimmunity.
[25] Edward Y. Kim,et al. TNFR2-Deficient Memory CD8 T Cells Provide Superior Protection against Tumor Cell Growth1 , 2009, The Journal of Immunology.
[26] D. Männel,et al. Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells1 , 2008, The Journal of Immunology.
[27] A. Godkin,et al. Regulatory T cells and tumour immunity – observations in mice and men , 2007, Immunology.
[28] P. Pandolfi,et al. Downstream of Tyrosine Kinases-1 and Src Homology 2-Containing Inositol 5′-Phosphatase Are Required for Regulation of CD4+CD25+ T Cell Development1 , 2006, The Journal of Immunology.
[29] S. Akira,et al. TLR signalling and the function of dendritic cells. , 2005, Chemical immunology and allergy.
[30] S. Akira,et al. Toll-like Receptors and Their Signaling Mechanisms , 2003, Scandinavian journal of infectious diseases.